▎ 摘　　要

NOVELTY - Polyacrylic acid/graphene oxide nanocomplex combined with supramolecular action, where the polyacrylic acid is obtained by combining adamantane and the cyclodextrin-modified graphene oxide by the supramolecular action of adamantane and a cyclodextrin. USE - The polyacrylic acid/graphene oxide nanocomplex is useful in medicinal carrier (claimed). DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for: (1) preparing a polyacrylic acid/graphene oxide nanocomposite combined with supramolecular action, comprising dissolving polyacrylic acid (AD-PAA) having a terminal adamantane and cyclodextrin-modified cerebral oxide (CD-GO), mixing in a ratio of 1:1 and stirring for 24 hours; (2) preparing polyammonium (AD-PAA) having an adamantane group by means of atom transfer radical polymerization (ATRP), comprising adding the treated CuBr, PMDETA, a mixed solvent of a 3:7 butanone solution and an isopropanol solution, and an adamantyl group-containing ATRP initiator (AD-Br) into the reaction tube, adding tert-butyl acrylate (PtBA), shaking uniformly to mix the mixed solution, reacting under anhydrous and oxygen-free at 90 degrees C for 12 hours, passing through a column of alumina, precipitating, and freeze-drying to obtain an AD-PtBA polymer, hydrolysing with trifluoroacetic acid and obtaining a adamantane as a terminal polyacrylic acid (AD-PAA); (3) preparing adamantyl group-containing ATRP initiator (AD-Br) by first taking amantadine and triethylamine in dry dichloromethane, adding bromoisobutyryl bromide at 0 degrees C, stirring in water bath with a magnetic stirrer for 1 hour under ice water bath conditions, reacting at room temperature for 12 hours, taking out the obtained product, filtering, rotary evaporating, passing through a silica gel column, combining the filtrates of the product, steaming again, drying to a white crystal and storing in a vacuum drying oven; (4) preparing cyclodextrin-modified graphene oxide (CD-GO), comprising dissolving beta -cyclodextrin in a dilute solution of sodium hydroxide, adding a solution of p-toluenesulfonyl chloride in acetonitrile, reacting at room temperature for 3 hours, suction filtration, and recrystallization to obtain p-toluenesulfonyl chloride modified beta -cyclodextrin compound, adding ethylenediamine and acetone to obtain a mono-(6-ethylenediamine-6-deoxy) beta -cyclodextrin (EDA-CD) intermediate, ultrasonically obtaining a well-dispersed aqueous graphene oxide solution, mixing and stirring potassium hydroxide and EDA-CD, reacting, obtaining a cloudy black solution, dialyzing and lyophilizing; and (5) use of the nanomaterial in medicinal carrier because the polyacrylic acid polymer attached to the graphene oxide by supramolecular action has pH responsiveness, loading the complex material with a drug having a conjugated system, and preventing the drug from being affected by the acidic environment of the stomach and the enzyme.